


# Pyridylthioureas

Alfa Aesar have introduced a new and innovative set of pyridylthioureas.


Pyridylthioureas have potential for the pharmaceutical sector having application in the formulation of pharmaceutical compositions for the reduction of gastric secretions for the treatment of gastric ulcers<sup>1</sup>.

2-Pyridyl thioureas have been developed as agonists for Somatostatin receptors for the study and development of non-peptide ligands for potential therapeutic activity<sup>2</sup>. Recent research highlights the importance of these compounds as intermediates for the generation of compounds providing therapeutic leads for the treatment of prion-disease<sup>3</sup> and Creutzfeld-Jakob disease<sup>4</sup> and are therefore a useful structural scaffold for pharmaceutical research and development.




**H33021**

N-(5-Bromo-3-methyl-2-pyridyl)thiourea, 97%




**H33063**

N-(5-Chloro-2-pyridyl)thiourea,  
97%  
[31430-27-0]




**H34088**

N-(5-Bromo-2-pyridyl)thiourea,  
97%  
[31430-38-3]




**H33648**

N-(4-Methyl-2-pyridyl)thiourea, 97%  
[21242-21-7]




**H33580**

N-(3-Bromo-5-methyl-2-pyridyl)thiourea, 98+%




**H33346**

N-(3-Methyl-2-pyridyl)thiourea,  
97%  
[41440-07-7]




**H34378**

N-(5-Methyl-2-pyridyl)thiourea,  
97%




**H33884**

N-(6-Methyl-2-pyridyl)thiourea,  
97%  
[49600-34-2]




**H33587**

N-(3,5-Dibromo-2-pyridyl)thiourea, 97%  
[31545-35-4]




**H34220**

N-(6-Bromo-2-pyridyl)thiourea,  
97%  
[439578-83-3]



**H33831**


N-(5-Fluoro-2-pyridyl)thiourea,  
97%



**H34440**


N-(3-Chloro-5-trifluoromethyl-2-pyridyl)thiourea, 97%

# Pyridylthioureas




**H33731**

N-(5-Trifluoromethyl-2-pyridyl)thiourea, 97%




**H34079**

N-(5-Bromo-6-methyl-2-pyridyl)thiourea, 97%




**H34014**

N-(3,5-Dibromo-6-methyl-2-pyridyl)thiourea, 97%




**H33343**

N-(6-Chloro-2-pyridyl)thiourea, 97%




**H34120**

N-(3,5-Dichloro-2-pyridyl)thiourea, 97%  
[31545-32-1]




**H33661**

N-(4,6-Dimethyl-2-pyridyl)thiourea, 97%  
[49600-35-3]




**H34009**

N-(5-Iodo-2-pyridyl)thiourea, 97%




**H33291**

N-(4-Chloro-2-pyridyl)thiourea, 97%




**H33465**

N-(3-Bromo-2-pyridyl)thiourea, 97%




**H33009**

N-(6-Methoxy-3-pyridyl)thiourea, 97%




**H33053**

N-(6-Chloro-3-pyridyl)thiourea, 97+%




**H34038**

N-(6-Bromo-3-pyridyl)thiourea, 97+%




**H33144**

N-(2,6-Dichloro-3-pyridyl)thiourea, 98+%



**H33664**

N-(2,6-Dibromo-3-pyridyl)thiourea, 97+%



**H33261**

N-(2-Chloro-4-pyridyl)thiourea, 98+%

1. Fake C.S. Potential for pharmaceutical compositions for the reductions of gastric secretions for the treatment of gastric ulcers. Patent 4224331. 1980.
2. Liu S., Crider A.M., Tang C. Ho B., Ankerson M., Stidsen C.E. 2-pyridylthioureas: novel nonpeptide somatostatin agonists with SST4 selectivity. *Curr. Phar. Des.* 1999, Apr 5(4), p. 255-263
3. Gallardo-Godoy, A., Genver J., Fife, K.L., Silber, M., Prusiner, S.B., Renslo, A.R. 2-Aminothiazoles as therapeutic leads for prion diseases. *J. Med. Chem.* 2011, V. 54, p. 1010-1021.
4. Creutzfeldt-Jakob disease. Breaking down the barrier. A glimmer of hope for a drug that treats disease caused by prions. *The Economist.* 2011, Web edition 23rd March.